Page 1 of 2621234567...Last »

The application of in vitro surveillance data for antibacterial dose selection.

The application of in vitro surveillance data for antibacterial dose selection. by Flamm RK, Sader HS, Castanheira M and Jones RN published in Curr Opin Pharmacol 2017; 36:130-138

Antimicrobial activity of aztreonam-avibactam and comparator agents tested against contemporary (2016) clinical Enterobacteriaceae isolates.

Antimicrobial activity of aztreonam-avibactam and comparator agents tested against contemporary (2016) clinical Enterobacteriaceae isolates. by Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK and Castanheira M published in Antimicrob. Agents Chemother. 2017 in press

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013-2016) as part of the surveillance program: Program to Assess Ceftolozane-Tazobactam Susceptibility.

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013-2016) as part of the surveillance program: Program to Assess Ceftolozane-Tazobactam Susceptibility. by Shortridge D, Pfaller MA, Castanheira M and Flamm RK published in Microb. Drug Resist. 2017; in press

Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers (2013-2016).

Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers (2013-2016). by Sader HS, Castanheira M, Shortridge D, Mendes RE and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (11): e01045

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: Report from an Antimicrobial Surveillance Program (2013-2015).

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: Report from an Antimicrobial Surveillance Program (2013-2015). by Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M and Flamm RK published in Braz. J. Infect. Dis. 2017; in press

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing health care-associated infections in the Asia-Pacific region (APAC; minus China, Australia and New Zealand): Report from an antimicrobial surveillance program (2013-2015).

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing health care-associated infections in the Asia-Pacific region (APAC; minus China, Australia and New Zealand): Report from an antimicrobial surveillance program (2013-2015). by Pfaller MA, Shortridge D, Sader HS, Castanheira M and Flamm RK Int. J. Antimicrob. Agents. 2017; in press

Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014).

Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). by Pfaller MA, Rhomberg PR, Huband MD and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2017; in press

Case report of transient mcr-1-haboring Escherichia coli with concurrent Staphylococcus aureus bacteremia in Long Beach, California.

Case report of transient mcr-1-haboring Escherichia coli with concurrent Staphylococcus aureus bacteremia in Long Beach, California. by Le J, Turner N, Deshpande LM, Davis AP and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2017; in press

In vitro activity of the novel lactone ketolide nafithromycin (WCK 4873) when tested against contemporary clinical bacteria from a global surveillance program. by Flamm RK, Rhomberg PR and Sader HS published in Antimicrob. Agents Chemother. 2017; in press.

Dilution factor of quantitative bacterial cultures obtained by bronchoalveolar lavage in patients with ventilator-associated bacterial pneumonia: Implications for optimal antimicrobial therapy ventilator-associated bacterial pneumonia study group.

Dilution factor of quantitative bacterial cultures obtained by bronchoalveolar lavage in patients with ventilator-associated bacterial pneumonia: Implications for optimal antimicrobial therapy ventilator-associated bacterial pneumonia study group. by Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo Torre CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M and Berman C published in Antimicrob. Agents Chemother. 2017; in press

Page 1 of 2621234567...Last »